VERTEX PHARMACEUTICALS INC / MA is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: Vertex Pharmaceuticals delivered a strong Q1 FY2026 with revenue of $2.99B (+7.8% YoY), operating income surging 80.6% to $1.14B, and net income jumping 59.6% to $1.03B, reflecting significant margin expansion and robust cash generation.
Drawn from management commentary in the Q1 2026 10-Q:
Total net revenues reached $2.99B in Q1 FY2026, up 7.8% from $2.77B in Q1 FY2025, indicating continued strong demand for Vertex's cystic fibrosis (CF) franchise and potentially contributions from newer product approvals.
Operating margin expanded approximately 15.4 percentage points YoY to 38.1% from 22.7%, driven by operating income growing 80.6% to $1.14B while revenue grew at a more modest 7.8%, suggesting significant operating leverage and/or one-time cost reductions in the prior year period.
SG&A expenses rose 24.5% YoY to $493.7M from $396.4M, outpacing revenue growth and suggesting increased commercial spending, potentially related to new product launches or expanded market access efforts.
Revenue
$2.99B
++7.82% YoY
EPS (Basic)
$4.06
++61.11% YoY
Operating Income
$1.14B
++80.62% YoY
Add VRTX to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.